Fulvestrant

氟维司群

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameFulvestrant
Drug Alias NameFulvestrantum氟维可群氟维司琼氟维斯群氟维思群 +[11] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionEstrogen receptors antagonistsEstrogen receptors degraders
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerPuberty, PrecociousLupus Erythematosus, Systemic +[11] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2002/04/25
Country/TerritoryCzechiaBelgiumCanada +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesCelcuity IncAstrazeneca Pharmaceutical Co LtdAstrazeneca Uk Ltd +[9] 
Inactive CompaniesDana-Farber Cancer InstituteUniversity Medical Center GroningenRoswell Park Cancer Institute +[18] 
Active IndicationsMetastatic breast cancerPuberty, PrecociousFibrous Dysplasia, Polyostotic +[5] 
Inactive IndicationsLupus Erythematosus, SystemicPulmonary Arterial HypertensionNeoplasm Metastasis +[6] 

Other Information

ATC CodeL02BA03
Related LinksWikipediaDrugBankKEGG